On March 6, 2018 Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, reported that Jeff Albers, Blueprint Medicines’ Chief Executive Officer, will present a company overview at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018 at 11:20 a.m. EST (Press release, Blueprint Medicines, MAR 6, 2018, View Source;p=RssLanding&cat=news&id=2336442 [SID1234524439]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting the Investors section of Blueprint Medicines’ website at View Source A replay of the webcast will be archived on Blueprint Medicines’ website for 30 days following the presentation.